ABSTRACT

FDA Regulation of Cannabidiol (CBD) Products [June 12, 2019]   [open pdf - 446KB]

"Cannabidiol (CBD) is promoted as treatment for a range of conditions, including epileptic seizures, post-traumatic stress disorder, anxiety, and inflammation--despite limited scientific evidence to substantiate many of these claims. In the United States, CBD is marketed in food and beverages, dietary supplements, and cosmetics--products that are regulated by the Food and Drug Administration (FDA). CBD is also the active ingredient in an FDA-approved pharmaceutical drug, Epidiolex®. CBD is a plant-derived substance from 'Cannabis sativa', the species of plant that includes both hemp and marijuana, but from different plant varieties or cultivars. CBD is the primary nonpsychoactive compound in cannabis, whereas tetrahydrocannabinol (THC) is cannabis's primary psychoactive compound."

Report Number:
CRS In Focus, IF11250
Author:
Publisher:
Date:
2019-06-12
Copyright:
Public Domain
Retrieved From:
Congressional Research Service: https://crsreports.congress.gov/
Format:
pdf
Media Type:
application/pdf
URL:
Help with citations